Biotechnology
Biopharmaceutical
Pharmaceutical

Intercept Pharmaceuticals

$84.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.48 (-1.71%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ICPT and other stocks, options, ETFs, and crypto commission-free!

About

Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Read More Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Employees
483
Headquarters
New York, New York
Founded
2002
Market Cap
2.57B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
700.48K
High Today
$86.32
Low Today
$84.25
Open Price
$85.48
Volume
175.91K
52 Week High
$133.74
52 Week Low
$65.63

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Research And Development
Technology

News

Yahoo FinanceMay 10

Intercept to Present at Upcoming Investor Conferences in May

NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conferences: Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV at 11:20 a.m. PT on Tuesday, May 14, 2019 in Las Vegas, NV at 11:20 a.m. PT on Tuesday, May 14, 2019 UBS Globa...

131
Yahoo FinanceMay 9

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

Intercept Pharmaceuticals, Inc. ICPT gained 3.02% after the company posted mixed results for the first quarter. The company reported a wider-than-expected loss but beat on sales expectations. The company incurred a loss of $3.03 per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of $2.57 but narrower than the year-ago loss of $3.22. Quarterly revenues were $52.2 million, up from $35.9 million in the year-ago quarter. Revenues also marginally surpassed the Zacks Consensus Est...

99
Yahoo FinanceMay 9

2 Reasons Intercept Pharmaceuticals Stock Tanked in April

What happened Intercept Pharmaceuticals (NASDAQ: ICPT), a commercial-stage liver disease specialist, lost a staggering 22.7% of its value in April, according to data from S&P Global Market Intelligence. What caused investors to hit the exits last month? Intercept's shares broke down in April for two reasons: Scroll to continue with content Ad The raging drug pricing debate in the United States weighed on nearly every biopharma stock last month. Not surprisingly, Intercept's shares proved to be no except...

164

Earnings

-$4.43
-$3.68
-$2.93
-$2.18
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$2.52 per share
Actual
-$3.03 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.